Orchestra BioMed appoints Andrew Taylor as CFO, Bill Little as EVP Corp Dev

Orchestra BioMed Holdings, Inc.

Michael Kaswan stepped down as CFO effective June 6, 2023; will consult at $36,180/month for up to 6 months.
Andrew Taylor appointed CFO; formerly CFO of Motus GI (MOTS), base salary $395,000, target bonus 50% of salary, initial equity grant of up to 278,502 RSUs or 417,544 options.
Bill Little appointed EVP of Corporate Development and Strategy; previously COO of Neovasc until its acquisition by Shockwave Medical.
Kaswan's consulting agreement includes $108,540 lump sum and additional three months' service vesting for equity.
Little to focus on strategic collaborations; partnerships with Medtronic and Terumo continue.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Taylor

Chief Financial Officer

OBIO · Orchestra BioMed Holdings, Inc.

Effective: 2023-06-06
Filed: June 8, 2023, 7:59 PM ET

the board of directors of the Company (the “Board”) appointed Mr. Andrew Taylor, age 52, as Chief Financial Officer of the Company to succeed Mr. Kaswan, effective as of the Separation Effective Date.

Departed

Michael Kaswan

Chief Financial Officer

OBIO · Orchestra BioMed Holdings, Inc.

Effective: 2023-06-06
Successor: Andrew Taylor
Filed: June 8, 2023, 7:59 PM ET

Mr. Michael Kaswan, the Company’s Chief Financial Officer, mutually agreed to terms pursuant to which Mr. Kaswan will step down as the Company’s Chief Financial Officer and separate from employment effective as of June 6, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Taylor was appointed as Chief Financial Officer at Orchestra BioMed Holdings, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the board of directors of the Company (the “Board”) appointed Mr. Andrew Taylor, age 52, as Chief Financial Officer of the Company to succeed Mr. Kaswan, effective as of the Separation Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Kaswan departed as Chief Financial Officer at Orchestra BioMed Holdings, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

Mr. Michael Kaswan, the Company’s Chief Financial Officer, mutually agreed to terms pursuant to which Mr. Kaswan will step down as the Company’s Chief Financial Officer and separate from employment effective as of June 6, 2023

View on SEC.gov

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-069440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.